This Biotech’s Next Trial Isn’t Just for Patients, It’s a Test for Your Portfolio

With an FDA Fast Track nod, a first‑in‑class schizophrenia therapy, and a 28% surge this week, this biotech is carving out a rare lane in brain health.

The question is whether today’s buyers are getting in early on a breakthrough, or just paying tomorrow’s price today.

Markets shift fast. Winners emerge faster.

Our analysts just pinpointed 5 breakout stocks—and free access ends at midnight.

Inside, you’ll get:

History shows these picks don’t stay quiet for long.

[Download your copy today]

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Text Here

Walmart (NYSE: WMT) is about to make your grocery run feel like a fintech flex.

Its app OnePay will soon let you buy, hold, and spend bitcoin and ether, thanks to a tie-up with startup Zerohash. Forget flashy headlines, this is crypto meeting the checkout lane.

If you’re wondering what makes it different, think about how often you already shop at Walmart.

Now picture those same trips pulling you into OnePay’s orbit. That’s loyalty on steroids.

One App to Rule Them All

OnePay isn’t just a wallet, it’s shaping up to be America’s first true super app.

Savings accounts, cards, wireless plans, BNPL, and now crypto — all wrapped into the brand you already see every week.

You don’t need to chase three other apps when Walmart is saying “just tap here.”

And here’s the kicker: OnePay is already outranking JPMorgan, Robinhood, and Chime in finance app downloads.

Add crypto and suddenly you’re looking at an ecosystem that competitors can’t easily copy.

The Bigger Flex

Walmart doesn’t just want your grocery money, it wants to be the hub for how you move money altogether.

If even a slice of those 150 million weekly shoppers start using OnePay for crypto, you’re staring at a retail giant quietly reinventing everyday finance.

Johnson & Johnson (NYSE: JNJ) just got the FDA green light to expand its autoimmune drug TREMFYA into kids six and older with psoriasis or psoriatic arthritis.

That’s not just good news for families, it’s a strategic win that extends the drug’s lifespan and secures more patients earlier in life.

When a treatment moves from adults into pediatrics, the addressable market grows instantly.

You’re not just treating today’s patients, you’re capturing loyalty for decades. That’s a quiet power move in pharma.

More Than Courtroom Headlines

Yes, J&J has its fair share of litigation noise and trade pressures, but approvals like this remind you what really drives the company. TREMFYA was already doing solid work in adults.

Now it’s the only biologic of its kind cleared for children, which locks in market share competitors can’t touch right away.

For you, it means J&J keeps finding ways to balance short-term headaches with long-term growth. When Wall Street shrugs at “boring,” this is how the company sneaks in upside.

The Real Punchline

If you thought J&J was just a sleepy play, think again.

The TREMFYA win shows the company can flex its innovation muscle while keeping its safe-stock aura. You might call that the best of both worlds.

When you turn on the TV, the talking heads are all covering the same tired stories…
Rate cuts. Trade disputes. Politics.

But according to one veteran market analyst, these headlines are nothing but noise.

Behind the scenes, he says a rare government-triggered event could quietly reshape the market as soon as October 9th.

He calls it the “Pivot Point.”

And based on historical patterns tied to past events like this, the opportunities have been remarkable — including rapid moves that stunned investors who weren’t prepared.

That’s why his team is going live on Wednesday, October 8th at 2 PM EST for a special emergency briefing.

If you want the details on how this October 9th event could spark a massive shift — and how to prepare before it hits — you’ll want to be in the room.

[Reserve your free spot now for the Pivot Point Briefing]

GlobalFoundries (NASDAQ: GFS) isn’t building the biggest GPUs or chasing buzzy AI headlines. Instead, it’s making the chips that keep your car running, your plane flying, and your 5G tower humming.

That may sound less glamorous, but it’s exactly why customers keep lining up.

When auto demand surged this year, GlobalFoundries’ automotive revenue jumped 36 percent.

Add in a solid 11 percent lift in communications and data centers, and you’ve got growth in the places that never really slow down.

You want boring reliability when it comes to semis, and that’s where this fab shines.

A U.S. Footprint That Matters

Unlike rivals who rely heavily on overseas factories, GlobalFoundries has massive plants in New York and Vermont.

That domestic base gives it resilience and makes it a natural partner for industries that need secure supply.

If you’re worried about fragile supply chains, this setup should give you a lot more confidence.

And the company isn’t standing still. Its recent MIPS acquisition boosts its intellectual property in AI and edge computing, meaning it’s expanding where the next wave of demand is forming.

You might not see its logo on a flashy product, but you’ll definitely be using its chips.

The Quiet Power Move

GlobalFoundries is building the tech backbone you use every day, even if you don’t see the logo. And that steady demand is exactly what makes it a sleeper win.

👉 Click here to get our closing report to your cell for free!

Alto Neuroscience Inc [ANRO] $6.90 (+56.35%)

Alto Neuroscience jumped after receiving FDA Fast Track designation for its novel schizophrenia cognitive treatment ALTO-101.

Lithium Americas Corp [LAC] $9.03 (+31.71%)

Lithium Americas continued to rally after USA Rare Earth’s CEO revealed direct talks with the White House, boosting hopes that Washington will deepen its strategic support for critical mineral players like itself.

Fuelcell Energy Inc [FCEL] $10.21 (+17.63%)

FuelCell spiked in sympathy with Plug Power after a major analyst upgrade triggered sector-wide enthusiasm for fuel cell demand.

American Rebel Holdings [AREB] $10.47 (-43.72%)

American Rebel shares declined after the company announced a 1-for-20 reverse stock split, often viewed as a red flag for distressed microcaps.

Aqua Metals Inc [AQMS] $6.99 (-8.63%)

Aqua Metals dipped after filing to register one million shares for resale, raising dilution fears among investors.

Roblox Corp [RBLX] $122.75 (-8.05%)

Roblox slid after analysts flagged sharply slowing bookings growth in the U.S. and Europe, its core markets.

Markets move fast — and the next 30 days could deliver opportunities most investors will miss.

We’ve narrowed down thousands of stocks to just 7 that meet strict earnings-based criteria and show the highest potential for immediate upside.

This system has historically delivered average annual gains of +24.2%, more than doubling the S&P 500 since 1988.

These aren’t random picks.

They’re carefully screened, ranked, and chosen as the best short-term plays available right now.

The clock is ticking.

If you wait, the window may close.

[Download your FREE copy of the 7 Best Stocks today]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.